Navigation Links
Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD
Date:10/31/2007

HENNIGSDORF and BERLIN, Germany, October 31 /PRNewswire/ -- Revotar Biopharmaceuticals AG., today announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD stage 0 to II (GOLD criteria) inhaling 70 mg of Bimosiamose twice a day. The study was conducted at the Charite - Medical School Charite Berlin, Prof. Witt and the Respiratory Institute Wiesbaden, Dr. Beeh. The results were presented during the recent European Respiratory Society Meeting in Stockholm in September.

"Despite of the short treatment period we were surprised to see that analysis of induced sputum prior to and after Bimosiamose treatment of 9 days showed that both relative and absolute lymphocytes count decreased significantly. In addition, sputum IL-8 was significantly decreased. The latter is supposed to correlate with the severity of the disease," commented Prof. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVP Research&Development at AstraZeneca, Germany. "Inhalation of Bimosiamose twice daily for up to 9 days was well tolerated and safe in patients. This targeted therapy provides the potential to prevent the further progression of inflammatory components in COPD and should be evaluated further in larger clinical trials," added Prof. Dr. Witt from the Charite and the Principal Investigator of the study.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises many serious conditions affecting the lung. More than 30 million people are living with COPD worldwide. COPD is the fourth leading cause of death and is responsible for more than 120,000 deaths a year in the US and Western Europe alone. The disease costs the US healthcare system US$40 billion per year.

About Revotar Biopharmaceutical AG

Revotar develops innovative anti-inflammatory drugs for inflammatory indications such as psoriasis, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Bimosiamose has already passed several clinical Phase I and Phase IIa trials in asthma and psoriasis with a good safety and efficacy profile in over 140 human beings. In summer 2006 Revotar announced the signing of a Start-Up Development Agreement with a US Pharma company for the further development of Bimosiamose in one major disease area. Revotar will present during the BioEurope conference in Hamburg on November 14, 2007.

Contact Address:

Stephan Tarlach

Executive Board

Revotar Biopharmaceuticals AG

Neuendorfstr. 24a

D-16761 Hennigsdorf

phone: +49-3302-2025040

fax: +49-3302-2025030

e-mail: s.tarlach@revotar-ag.de

http://www.revotar.de


'/>"/>
SOURCE Revotar Biopharmaceutics AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):